The challenges and complexities of thyroid hormone replacement

Laboratory Medicine

Volumn 41, Issue 6, 2010, Pages 338-348

  Kansagra, Shayri M ^a   McCudden, Christopher R ^b   Willis, Monte S ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Combination therapy; Hypothyroidism; Thyroid gland; Thyroid hormone; Thyroxine (T4); Triiodothyronine (T3)

Indexed keywords

CALCIUM CARBONATE; CATECHOLAMINE; IRON; LEVOTHYROXINE; LIOTHYRONINE; LIOTRIX; LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE; MONOCARBOXYLATE TRANSPORTER; PHENYTOIN; RIFAMPICIN; SEROTONIN; THYROTROPIN; THYROXINE;

COGNITION; COGNITIVE DEFECT; DEIODINATION; DIAGNOSTIC TEST; DRUG DOSE COMPARISON; FATIGUE; GRAVES DISEASE; HASHIMOTO DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LETHARGY; MAJOR DEPRESSION; MENTAL HEALTH; MONOTHERAPY; MOOD DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PSYCHIATRIC TREATMENT; REVIEW; THYROIDECTOMY; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 77953062768     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/LMB39TH2FZGNDGIM     Document Type: Review

References (88)

1. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: The Whickham survey. Clin Endocrinol (Oxf). 1977;7:481-493. (Pubitemid 8235965)
2. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43:55-68.
3. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-534. (Pubitemid 30112276)
4. Dillmann WH. Biochemical basis of thyroid hormone action in the heart. Am J Med. 1990;88:626-630. (Pubitemid 20192278)
5. Honbo KS, van Herle AJ, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med. 1978;64:782-787. (Pubitemid 8328125)
6. Donnelly P, White C. Testicular dysfunction in men with primary hypothyroidism; reversal of hypogonadotrophic hypogonadism with replacement thyroxine. Clin Endocrinol (Oxf). 2000;52:197-201. (Pubitemid 30108266)
7. Carani C, Isidori AM, Granata A, et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab. 2005;90:6472-6479. (Pubitemid 41759302)
8. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf). 1999;50:655-659.
9. Leigh H, Kramer SI. The psychiatric manifestations of endocrine disease. Adv Intern Med. 1984;29:413-445.
10. Haupt M, Kurz A. Reversibility of dementia in hypothyroidism. J Neurol. 1993;240:333-335.
11. Franchini M, Lippi G, Manzato F, et al. Hemostatic abnormalities in endocrine and metabolic disorders. Eur J Endocrinol [Epub]. November 24, 2009.
12. Bruni JF, Marshall S, Dibbet JA, et al. Effects of hyper- and hypothyroidism on serum LH and FSH levels in intact and gonadectomized male and female rats. Endocrinology. 1975;97:558-563.
13. Krassas GE, Papadopoulou F, Tziomalos K, et al. Hypothyroidism has an adverse effect on human spermatogenesis: A prospective, controlled study. Thyroid. 2008;18:1255-1259.
14. Halpern JP, Boyages SC, Maberly GF, et al. The neurology of endemic cretinism. A study of two endemias. Brain. 1991;114:825-841.
15. Cao XY, Jiang XM, Dou ZH, et al. Timing of vulnerability of the brain to iodine deficiency in endemic cretinism. N Engl J Med. 1994;331:1739-1744.
16. Williams GR. Neurodevelopmental and neurophysiological actions of thyroid hormone. J Neuroendocrinol. 2008;20:784-794. (Pubitemid 351858730)
17. Samuels MH. Cognitive function in untreated hypothyroidism and hyperthyroidism. Curr Opin Endocrinol Diabetes Obes. 2008;15:429-433.
18. Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Endocr Pract. 2004;10:497-501. (Pubitemid 40223495)
19. Bunevicius R, Kazanavicius G, Zalinkevicius R, et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med. 1999;340:424-429. (Pubitemid 29084773)
20. Samuels MH, Ridgway EC. Central hypothyroidism. Endocrinol Metab Clin North Am. 1992;21:903-919.
21. Evered DC, Ormston BJ, Smith PA, et al. Grades of hypothyroidism. Br Med J. 1973;1:657-662.
22. Roberts CG, Ladenson PW. Hypothyroidism. Lancet. 2004;363:793-803.
23. Weetman AP, McGregor AM. Autoimmune thyroid disease: Further developments in our understanding. Endocr Rev. 1994;15:788-830.
24. Sridama V, McCormick M, Kaplan EL, et al. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med. 1984;311:426-432. (Pubitemid 14058253)
25. Franklyn JA, Daykin J, Drolc Z, et al. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf). 1991;34:71-76.
26. Cunnien AJ, Hay ID, Gorman CA, et al. Radioiodine-induced hypothyroidism in Graves' disease: Factors associated. J Nucl Med. 1982;23:978-983.
27. Means JH, DeGroot LJ, Stanbury JB, eds. The Thyroid and Its Diseases. New York, NY: McGraw-Hill; 1963.
28. Braverman LE, Ingbar SH, Sterling K. Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects. J Clin Invest. 1970;49:855-864.
29. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA. 1995;273:808-812.
30. Roos A, Linn-Rasker SP, van Domburg RT, et al. The starting dose of levothyroxine in primary hypothyroidism treatment: A prospective, randomized, double-blind trial. Arch Intern Med. 2005;165:1714-1720. (Pubitemid 41138957)
31. Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med. 1987;316:764-770. (Pubitemid 17046084)
32. Bach-Huynh TG, Nayak B, Loh J, et al. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab. 2009;94:3905-3912
33. Oppenheimer JH, Braverman LE, Toft A, et al. A therapeutic controversy. Thyroid hormone treatment: When and what? J Clin Endocrinol Metab. 1995;80:2873-2883.
34. Dong BJ, Hauck WW, Gambertoglio JG, et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA. 1997;277:1205-1213. (Pubitemid 27172743)
35. Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium. Thyroid. 2004;14:486.
36. Rees-Jones RW, Larsen PR. Triiodothyronine and thyroxine content of desiccated thyroid tablets. Metabolism. 1977;26:1213-1218.
37. Saravanan P, Chau WF, Roberts N, et al. Psychological well-being in patients on "adequate" doses of l-thyroxine: Results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57:577-585.
38. Escobar-Morreale HF, del Rey FE, Obregon MJ, et al. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology. 1996;137:2490-2502.
39. Cooper DS. Combined T4 and T3 therapy - Back to the drawing board. JAMA. 2003;290:3002-3004.
40. Clyde PW, Harari AE, Getka EJ, et al. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: A randomized controlled trial. JAMA. 2003;290:2952-2958.
41. Sawka AM, Gerstein HC, Marriott MJ, et al. Does a combination regimen of thyroxine (T4) and 3,5,3 -triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. J Clin Endocrinol Metab. 2003;88:4551-4555.
42. Siegmund W, Spieker K, Weike AI, et al. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14:1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf). 2004;60:750-757.
43. Walsh JP, Shiels L, Lim EM, et al. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: A randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab. 2003;88:4543-4550. (Pubitemid 37357490)
44. Bunevicius R, Jakubonien N, Jurkevicius R, et al. Thyroxine vs thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves' disease. Endocrine. 2002;18:129-133.
45. Rodriguez T, Lavis VR, Meininger JC, et al. Substitution of liothyronine at a 1:5 ratio for a portion of levothyroxine: Effect on fatigue, symptoms of depression, and working memory versus treatment with levothyroxine alone. Endocr Pract. 2005;11:223-233.
46. Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, et al. Thyroid hormone replacement therapy in primary hypothyroidism: A randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med. 2005;142:412-424. (Pubitemid 40365429)
47. Saravanan P, Simmons DJ, Greenwood R, et al. Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: Results of a large community-based randomized controlled trial. J Clin Endocrinol Metab. 2005;90:805-812. (Pubitemid 40279201)
48. Horn S, Heuer H. Thyroid hormone action during brain development: More questions than answers. Mol Cell Endocrinol [Epub]. September 16, 2009.
49. Crantz FR, Silva JE, Larsen PR. An analysis of the sources and quantity of 3,5,3 -triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex and cerebellum. Endocrinology. 1982;110:367-375.
50. Guadano-Ferraz A, Obregon MJ, St Germain DL, et al. The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain. Proc Natl Acad Sci USA. 1997;94:10391-10396. (Pubitemid 27407052)
51. Galton VA, Wood ET, St Germain EA, et al. Thyroid hormone homeostasis and action in the type 2 deiodinase-deficient rodent brain during development. Endocrinology. 2007;148:3080-3088.
52. St Germain DL, Galton VA, Hernandez A. Minireview: Defining the roles of the iodothyronine deiodinases: Current concepts and challenges. Endocrinology. 2009;150:1097-1107.
53. Galton VA, Schneider MJ, Clark AS, et al. Life without thyroxine to 3,5,3 -triiodothyronine conversion: Studies in mice devoid of the 5 -deiodinases. Endocrinology. 2009;150:2957-2963.
54. Tu HM, Legradi G, Bartha T, et al. Regional expression of the type 3 iodothyronine deiodinase messenger ribonucleic acid in the rat central nervous system and its regulation by thyroid hormone. Endocrinology. 1999;140:784-790. (Pubitemid 29058213)
55. Schweizer U, Weitzel JM, Schomburg L. Think globally: Act locally. New insights into the local regulation of thyroid hormone availability challenge long accepted dogmas. Mol Cell Endocrinol. 2008;289:1-9.
56. Sugiyama D, Kusuhara H, Taniguchi H, et al. Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: High affinity transporter for thyroxine. J Biol Chem. 2003;278:43489-43495. (Pubitemid 37345972)
57. Tohyama K, Kusuhara H, Sugiyama Y. Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology. 2004;145:4384-4391. (Pubitemid 39120588)
58. Heuer H, Maier MK, Iden S, et al. The monocarboxylate transporter 8 linked to human psychomotor retardation is highly expressed in thyroid hormone-sensitive neuron populations. Endocrinology. 2005;146:1701-1706. (Pubitemid 40396877)
59. Trajkovic M, Visser TJ, Mittag J, et al. Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. J Clin Invest. 2007;117:627-635. (Pubitemid 46348521)
60. Friesema EC, Docter R, Moerings EP, et al. Thyroid hormone transport by the heterodimeric human system L amino acid transporter. Endocrinology. 2001;142:4339-4348. (Pubitemid 32907062)
61. Friesema EC, Jansen J, Jachtenberg JW, et al. Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Mol Endocrinol. 2008;22:1357-1369. (Pubitemid 351786996)
62. Bassett JH, Harvey CB, Williams GR. Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol Cell Endocrinol. 2003;213:1-11.
63. Flamant F, Samarut J. Thyroid hormone receptors: Lessons from knockout and knock-in mutant mice. Trends Endocrinol Metab. 2003;14:85-90. (Pubitemid 36733921)
64. Ercan-Fang S, Schwartz HL, Oppenheimer JH. Isoform-specific 3,5,3 -triiodothyronine receptor binding capacity and messenger ribonucleic acid content in rat adenohypophysis: Effect of thyroidal state and comparison with extrapituitary tissues. Endocrinology. 1996;137:3228-3233. (Pubitemid 26250168)
65. Forrest D, Vennstrom B. Functions of thyroid hormone receptors in mice. Thyroid. 2000;10:41-52. (Pubitemid 30090364)
66. Bernal J. Thyroid hormone receptors in brain development and function. Nat Clin Pract Endocrinol Metab. 2007;3:249-259. (Pubitemid 46310532)
67. O'Shea PJ, Williams GR. Insight into the physiological actions of thyroid hormone receptors from genetically modified mice. J Endocrinol. 2002;175:553-570.
68. Moeller LC, Cao X, Dumitrescu AM, et al. Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor beta through the phosphatidylinositol 3-kinase pathway. Nucl Recept Signal. 2006;4:e020.
69. Hiroi Y, Kim HH, Ying H, et al. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA. 2006;103:14104-14109.
70. Davis PJ, Davis FB, Cody V. Membrane receptors mediating thyroid hormone action. Trends Endocrinol Metab. 2005;16:429-435. (Pubitemid 41506950)
71. Farwell AP, Dubord-Tomasetti SA, Pietrzykowski AZ, et al. Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3,5 -triiodothyronine. Brain Res Dev Brain Res. 2005;154:121-135.
72. Leonard JL. Non-genomic actions of thyroid hormone in brain development. Steroids. 2008;73:1008-1012.
73. Harper ME, Seifert EL. Thyroid hormone effects on mitochondrial energetics. Thyroid. 2008;18:145-156. (Pubitemid 351271528)
74. Scanlan TS. Minireview: 3-Iodothyronamine (T1AM): A new player on the thyroid endocrine team? Endocrinology. 2009;150:1108-1111.
75. Cleare AJ, McGregor A, O'Keane V. Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol (Oxf). 1995;43:713-719. (Pubitemid 26016802)
76. Hendrick V, Altshuler L, Whybrow P. Psychoneuroendocrinology of mood disorders. The hypothalamic-pituitary-thyroid axis. Psychiatr Clin North Am. 1998;21:277-292. (Pubitemid 28311851)
77. Heal DJ, Smith SL. The effects of acute and repeated administration of T3 to mice on 5-HT1 and 5-HT2 function in the brain and its influence on the actions of repeated eletroconvulsive shock. Neuropharmacology. 1998;27:1239-1248.
78. Kelly T, Lieberman DZ. The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. J Affect Disord. 2009;116:222-226.
79. Abraham G, Milev R, Stuart Lawson J. T3 augmentation of SSRI resistant depression. J Affect Disord. 2006;91:211-215.
80. Cooper-Kazaz R, van der Deure WM, Medici M, et al. Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affect Disord. 2009;116:113-116.
81. Posternak M, Novak S, Stern R, et al. A pilot effectiveness study: Placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. Int J Neuropsychopharmacol. 2008;11:15-25.
82. Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry. 2001;158:1617-1622. (Pubitemid 32923653)
83. Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53:842-848. (Pubitemid 26303624)
84. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report. Am J Psychiatry. 2006;163:1519-1530; quiz 1665. (Pubitemid 44464443)
85. Carvalho AF, Machado JR, Cavalcante JL. Augmentation strategies for treatment-resistant depression. Curr Opin Psychiatry. 2009;22:7-12.
86. Grozinsky-Glasberg S, Fraser A, Nahshoni E, et al. Thyroxine- triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: Meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2006;91:2592-2599. (Pubitemid 44024623)
87. Pilo A, Iervasi G, Vitek F, et al. Thyroidal and peripheral production of 3,5,3 -triiodothyronine in humans by multicompartmental analysis. Am J Physiol. 1990;258:E715-726. (Pubitemid 20142356)
88. Taylor S, Kapur M, Adie R. Combined thyroxine and triiodothyronine for thyroid replacement therapy. Br Med J. 1970;2:270-271.